Pathologic Complete Response After Neoadjuvant Chemoradiation in a Patient with Gastric Neuroendocrine Cancer

Neuroendocrine tumors are about 0.5% of all malignancies. Specifically, for gastrointestinal (GI) malignancies, neuroendocrine tumor incidence is approximately 1%-2% per year. Gastric neuroendocrine neoplasms are rare and consist of various tumor types with differing histomorphology, pathogenesis, and biological behavior. Following surgery, post-operative chemotherapy is generally considered the standard of care. Our case report demonstrates the potential benefit of neoadjuvant concurrent chemoradiotherapy prior to surgery for a malignant gastric neuroendocrine tumor. While radiotherapy has been demonstrated to possibly provide a survival benefit in the treatment of GI neuroendocrine tumors, its use in treatment, particularly neoadjuvantly, needs to be further assessed.